LIF - A Predictor of Immunotherapy Resistance
Description
Primary reference:
Loriot Y and Italiano A et al. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. (2021) 32(11):1381-1390. doi:10.1016/j.annonc.2021.08.1748
Olink Insight Knowledge Platform with Hilda Andersson, Episode 6, Proteomics in Proximity.
Description of the MATCH-R clinical trial, “A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents (MATCH-R)”, NCT02517892
In case you were wondering, Proteomics in Proximity refers to the principle underlying Olink Proteomics assay technology called the Proximity Extension Assay (PEA), and more information about the assay and how it works can be found here.
Would you like to subscribe to the podcast on your favorite player or app? You can do so here:
Apple Podcasts: https://apple.co/3T0YbSm
Spotify Podcasts: https://open.spotify.com/show/2sZ2wxOqI4b4vSngkajLs8?si=d957d55c8db046f7 Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy50cmFuc2lzdG9yLmZtL3Byb3Rlb21pY3MtaW4tcHJveGltaXR5
Amazon Music: https://music.amazon.com/podcasts/d97ace94-f02b-4b37-9532-799548ef2840
Podcast Addict: https://podcastaddict.com/podcast/4098296
Deezer: https://www.deezer.com/show/5178787
Player FM: https://player.fm/series/series-3396598
United States
